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Adrenal masses are mainly detected unexpectedly by an imaging study performed for reasons unrelated to any suspect of adrenal 
diseases. Such masses are commonly defined as “adrenal incidentalomas” and represent a public health challenge because they are 
increasingly recognized in current medical practice. Management of adrenal incidentalomas is currently matter of debate. Although 
there is consensus on the need of a multidisciplinary expert team evaluation and surgical approach in patients with significant hor-
monal excess and/or radiological findings suspicious of malignancy demonstrated at the diagnosis or during follow-up, the inconsis-
tency between official guidelines and the consequent diffuse uncertainty on management of small adrenal incidentalomas still repre-
sents a considerable problem in terms of clinical choices in real practice. The aim of the present work is to review the proposed strat-
egies on how to manage patients with adrenal incidentalomas that are not candidates to immediate surgery. The recent European So-
ciety of Endocrinology/European Network for the Study of Adrenal Tumors guidelines have supported the view to avoid surveil-
lance in patients with clear benign adrenal lesions <4 cm and/or without any hormonal secretion; however, newer prospective stud-
ies are needed to confirm safety of this strategy, in particular in younger patients.
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INTRODUCTION
Adrenal masses are mainly detected unexpectedly by an imag-
ing study performed for reasons unrelated to any suspect of ad-
renal diseases [1,2]. Such masses are commonly defined as “ad-
renal incidentalomas” and represent a public health challenge 
because they are increasingly recognized in current medical 
practice. 
The frequency of adrenal incidentalomas in computed tomog-
raphy (CT) series assessed in the 1980s and ‘90s ranged from 
0.35% to 1.9% [3-8], but more recent studies have reported a 
frequency of about 4.2% to 7.3% [9-12] that may increase up to 
10% in elderly population. The etiology of adrenal incidentalo-
mas includes mostly benign non-secreting adenomas, however 
a number of lesions are malignant or are hormone producing 
(pheochromocytoma, aldosterone producing adenoma, and cor-
tisol producing adenoma). 
Up to 20% of patients bearing an incidental adrenal adenoma 
present the so-called subclinical Cushing syndrome, even if 
there is no consensus on how to secure the diagnosis [13-15]. In 
this area of controversy, we have proposed the following diag-
nostic criteria: first, the adrenal mass should have radiologic 
characteristics of adrenal adenoma; second, the patient should 
not present any specific Cushingoid sign; third, the endocrine 
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work-up should demonstrate partial autonomous (pituitary adre-
nocorticotropic independent) cortisol secretion [14]. Several 
studies have shown that this low-grade cortisol excess may be 
associated with various comorbid conditions (hypertension, 
type 2 diabetes mellitus, obesity, dyslipidemia, and osteoporo-
sis) [13,16,17]. Therefore, the term subclinical is equivocal be-
cause the condition may have clinical consequences and, for 
these reasons, the recent European Society of Endocrinology 
(ESE) guidelines abandoned the term “subclinical Cushing syn-
drome” for “autonomous cortisol secretion” [2].
Management of adrenal incidentalomas is currently matter of 
debate. There is consensus on the need of a multidisciplinary 
expert team evaluation and surgical approach in patients with 
significant hormonal excess and/or radiological findings suspi-
cious of malignancy demonstrated at the diagnosis or during 
follow-up. The aim of the present work is to review the pro-
posed strategies on how to manage patients with adrenal inci-
dentalomas that are not candidates to immediate surgery, since 
there is no consensus on what type of follow-up, if any, is need-
ed [1,2,18-23].
STRATEGIES OF RADIOLOGICAL 
FOLLOW-UP
Available guidelines [2,18,21,23] and consensus statements 
[1,19,20,22] diverge on indications for surveillance of benign-
appearing adrenal incidentalomas in order to detect malignant 
transformation (Table 1). The ESE/European Network for the 
Study of Adrenal Tumors (ENSAT) guidelines, recommend first 
to establish the risk of malignancy of an adrenal mass at the 
time of initial detection [2]. An adrenal mass is considered be-
nign if appears homogeneous and lipid-rich, with a density ≤10 
Hounsfield units (HU) at an unenhanced CT scan. 
For adrenal masses smaller than 4 cm with benign features, 
the ESE/ENSAT guidelines [2] and Korean guidelines [23] sug-
gest that no further imaging is required. This is a debated point, 
since previous recommendations indicated the need to repeat an 
imaging (i.e., a CT scan) in all patients at a 3 to 6 months 
[1,18,22], or 6 to 12 months interval [19-21]. Moreover, some 
guidelines recommended continuing the radiological follow-up 
annually [18,22], or every 2 years [20] for 4 to 5 years, without 
considering any mass size at diagnosis to guide the decision 
process for the follow-up [18-20]. The most recent recommen-
dations extend the idea to limit follow-up introduced by the Ital-
ian “Associazione Medici Endocrinologi” (AME) position 
statement, that suggested to not perform any further imaging 
test in very small (<1 to 2 cm) benign masses or in masses with 
clear benign features (i.e., myelolipomas, hemorrhages, cysts) 
[1,21]. 
The ESE/ENSAT guidelines recommend a single follow-up 
test (non-contrast CT or magnetic resonance imaging) after 6 to 
12 months for adrenal masses larger than 4 cm at diagnosis, or 
for adrenal masses with indeterminate characteristics, to ex-
clude significant growth [2]. For these patients, a multidisci-
plinary team evaluation should identify the best option between 
immediate surgical treatment or additional imaging evaluation 
with another technique [2]. However, this is a weak recommen-
dation supported by a very low level of evidence that leaves un-
certainties in its application, since it requires a bit of personal 
judgment.
Benign masses are not expected to grow significantly in this 
time interval, but there are no evidence-based cut-offs of size 
increase to support suspicion of malignancy. In fact, different 
cut-offs of size increase that should lead to surgical resection 
have been proposed. A growth of 5 mm or of 20% in size is con-
sidered as significant and should lead to surgical resection for 
the ESE/ENSAT guidelines [2], while for the Canadian [21] and 
the Korean [23] guidelines the cut-offs are between 0.8–1 cm 
and 0.5–1 cm, respectively (Table 1). 
In 2017, Hong et al. [24] published a reappraisal of the ESE/
ENSAT guidelines in real clinical practice on a retrospective co-
hort of 1,149 patients managed at a single center in South Korea 
(Seoul) between 2000 and 2013 with a median follow-up of 4 
years. Data were analyzed with the aim to evaluate the diagnos-
tic value of mass size and density to detect malignant lesions. 
The optimal cut-off values to distinguish malignant from benign 
lesions were 3.4 cm for mass size and 19.9 HU for density at 
unenhanced CT. Therefore, this retrospective study validates the 
indication of the ESE/ENSAT guidelines to avoid any imaging 
follow-up in adrenal masses with density <10 HU and size <4 
cm at unenhanced CT.
A recent systematic review and meta-analysis of the literature 
by Elhassan et al. [25] confirmed that most of the non-function-
ing adrenal adenomas and adenomas causing mild autonomous 
cortisol excess do not show significant growth in size during 
their follow-up. Only 2.5% of adrenal adenomas grew by 10 
mm or more over an average follow-up of 41.5 months and, 
again, malignant transformation was never observed. This anal-
ysis pointed out that tumors >25 mm had a lower rate of growth 
during follow-up than smaller ones, suggesting the achievement 
of a maximum growth potential of benign lesions [26]. The use 
of a growth cut-off during long term follow-up was not superior 
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Table 1. Comparison among Consensus/Guidelines on Radiological Follow-up
Consensus/Guidelines Year of publication Country Recommendation/Suggestion
Level of 
evidence
National Institutes of Health (NIH)  
consensus conference [19]
2002 United 
States
Repeat a CT scan at 6–12 months. If there is not an increase in 
size, follow-up should be ended.
Exploration and management of adrenal 
incidentalomas. French Society of  
Endocrinology Consensus [20]
2008 France Repeat a CT scan at 6 months to rule out the very-low risk of 
overlooking a malignant tumor. Repeat a CT scan at 2 years and 
at 5 years to checking for long-term malignant risk.
American Association of Clinical  
Endocrinologists/American Association 
of Endocrine Surgeons (AACE/AAES) 
guideline [18]
2009 United 
States
Repeat an imaging at 3–6 months and then annually for 1–2 years Grade C; Evidence 
Level 3
Guidelines for the management of the 
incidentally discovered adrenal mass 
[21]
2011 Canada No further imaging in patients with a benign appearing mass  
<1 cm or in patients with benign etiologies at discovery  
(myelolipomas, hemorrhages, cysts). 
Grade D; Evidence 
Level 4
Recommendation 
Repeat imaging after 12 months (preferably of the same modality 
used at diagnosis) for masses of 1–2 cm if the clinical picture 
warrants (consider no follow-up if imaging is stable). 
Repeat imaging after 12 months for masses 2–4 cm: if stable, con-
sider no follow-up while if not stable consider surgical removal 
or close follow-up (3–6 months). If a mass exhibits an increase 
in size (greater than 0.5–1 cm) consider surgical removal.
Grade C; Evidence 
Level 3
Recommendation
Italian Association of Clinical  
Endocrinologists (AME) position 
statement [1]
2011 Italy In general, repeat a CT scan at 3–6 months. 
No further imaging in patients with small tumors (<2 cm). For 
larger tumors the decision should be based on the characteristics 
of the mass, patient age and history, results of endocrine work-
up.
Adrenal incidentaloma in adults— 
management recommendations by the 
Polish Society of Endocrinology [22]
2016 Poland If the tumor is small (≤3 cm) and resembles a typical lipid-rich 
adenoma, imaging tests are recommended annually. In the cases 
of larger tumors, or those with a less characteristic phenotype, 
consider imaging check-ups every 3–6 months within the first 
year, and later every 12 months.
If the lesion is not oncological suspicious and is stable, stop  
follow-up after 4 years.
European Society of Endocrinology/
European Network for the Study of 
Adrenal Tumors (ESE/ENSAT) 
guideline [2]
2016 Europe No further imaging in patients with an adrenal mass <4 cm with 
clear benign features on imaging studies.
Repeat a non-contrast CT scan or MRI at 6–12 months in patients 
with a mass >4 cm or with indeterminate characteristics at the 
first imaging.
If there is growth of the lesion less than 20% of the largest  
diameter during this period, additional imaging after 6–12 
months should be performed (in case of growth >20% and at 
least a 5 mm increase in maximum diameter, the patient should 
be evaluated for surgical resection).
Weak recommen-
dation; Evidence 
Level very low
Weak recommen-
dation; Evidence 
Level very low
Clinical Guidelines for the Management 
of Adrenal Incidentaloma [23]
2017 Korea No further imaging in patients with an adrenal mass <4 cm with 
clear benign features on initial work-up.
Repeat a CT scan at 3–6 months and then annually for 1–2 years 
in patients with a mass <4 cm and >10 HU.
In case of repeated imaging follow-up, no further exams are re-
quired if the tumor does not change in size over a period of more 
than 1 year, but if a mass with indeterminate radiological features 
increases in size more than 0.8–1 cm during 3–12 months of fol-
low-up or it changes its appearance, consider an adrenalectomy. 
Recommendation 
Level C
CT, computed tomography; MRI, magnetic resonance imaging; HU, Hounsfield unit.
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to the assessment of baseline imaging characteristics in the 
identification of suspicious adrenal masses [25]. This concept is 
confirmed in a recent, small, retrospective study reporting a tu-
mor growth ≥1.0 cm in almost 9% of patients, even if none of 
them was found to be malignant [27]. 
Despite growing evidence is supporting the strategy suggest-
ed by the ESE/ENSAT guidelines, prospective studies are still 
lacking to definitively validate this approach.
STRATEGIES OF BIOCHEMICAL FOLLOW-
UP
Although there is a consensus that every patient with an adrenal 
incidentaloma at diagnosis should undergo careful assessment 
including clinical examination for symptoms and signs of adre-
nal hormone excess and an adequate biochemical evaluation, 
less evidence is available on how these patients should be ex-
amined during follow-up [1,2,19-23].
At diagnosis, the ESE/ENSAT guidelines [2], following the 
Italian AME Position Statement [1], proposed that serum corti-
sol levels after 1 mg-dexamethasone suppression test (DST) ≤
50 nmol/L (≤1.8 μg/dL) safely exclude autonomous cortisol se-
cretion. Levels between 51 and 138 nmol/L (1.9 to 5.0 μg/dL) 
should be considered as evidence of ‘possible autonomous cor-
tisol secretion’ and cortisol levels >138 nmol/L (>5.0 μg/dL) 
should be taken as evidence of ‘autonomous cortisol secretion.’ 
This cut-off is supported by studies demonstrating that patients 
with post-DST cortisol >50 nmol/L (>1.8 μg/dL) have in-
creased morbidity or mortality [28,29]. Moreover, the same 
panel suggests to exclude pheochromocytoma by measuring 
plasma-free or urinary fractionated metanephrines and to ex-
clude primary hyperaldosteronism by measuring the aldoste-
rone/renin ratio in patients with hypertension or unexplained 
hypokalemia.
Reported evidence supports the idea that during follow-up 
patients with clinically unapparent cortisol excess very rarely 
develop Cushing syndrome [14,30-34], which is clearly associ-
ated with severe morbidity and elevated mortality [35-39]. The 
previously cited metanalysis by Elhassan et al. [25] reported 
that only six out of 2,745 patients with either non-functioning 
adrenal tumors or tumors causing mild autonomous cortisol ex-
cess developed overt Cushing syndrome. Therefore, it is plainly 
evident that ‘autonomous cortisol secretion’ is not a condition 
associated with a high risk to develop overt Cushing syndrome. 
Nevertheless, it has been shown that low-grade autonomous 
cortisol excess might be associated with comorbidities (hyper-
tension, glucose intolerance/type 2 diabetes mellitus, obesity, 
dyslipidemia, osteoporosis) [2,40], without being a preliminary 
stage of overt Cushing syndrome [26].
The ESE/ENSAT guidelines [2] suggest annual clinical reas-
sessment of comorbidities related to cortisol excess in patients 
with ‘autonomous cortisol secretion’ without signs of overt 
Cushing syndrome and in patients with both ‘possible autono-
mous cortisol secretion’ and potentially associated comorbidities. 
A critical point of discussion is how to follow the patients 
with a normal hormonal work-up at the initial evaluation. The 
ESE/ENSAT guidelines do not recommend repeating hormonal 
workup unless new clinical signs of endocrine activity appear, 
or there is worsening of comorbidities (e.g., hypertension, glu-
cose intolerance/type 2 diabetes mellitus, obesity, dyslipidemia) 
[2]. This is in line with what was suggested by the Italian AME 
Position Statement [1] although several guidelines [18] or con-
sensus positions [19,20,22] proposed biochemical follow-up 
every year in all patients using different hormonal tests (Table 
2). More recently, the Korean guidelines [23] recommended an 
annual screening for 4 to 5 years to detect a possible change in 
functionality of the tumors when they are larger than 2 cm.
Hong et al. [24] in their retrospective cohort study showed 
that 28% of patients with non-functioning adrenal tumors at di-
agnosis progressed to autonomous cortisol secretion during fol-
low-up, but none of them developed Cushing syndrome. This 
seems to validate the indications suggested by ESE/ENSAT 
guidelines, although prospective studies with a longer follow-up 
would be needed to confirm the appropriate follow-up strategy.
IT IS CONCEIVABLE THAT NON-
FUNCTIONING ADENOMAS ARE 
ASSOCIATED TO COMORBID 
CONDITIONS?
Although the meta-analysis by Elhassan et al. [25] included 
studies with few patients and heterogeneous definitions of au-
tonomous cortisol excess, it demonstrated that the prevalence of 
cardiovascular risk factors (such as hypertension, obesity, dys-
lipidemia, and type 2 diabetes) was higher than expected also in 
patients with non-functioning tumors. Surprisingly, mortality 
from cardiovascular disease during follow-up of patients with 
non-functioning tumors was similar to those of patients with 
mild autonomous cortisol secretion. Why non-functioning tu-
mors are associated with comorbid conditions remains unclear. 
It is plausible that diseased individuals are more frequently 
subjected to imaging tests that can lead to the detection of an 
Reimondo G, et al.
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adrenal incidentaloma. An alternative explanation is that meta-
bolic syndrome and diabetes may promote development of ad-
renal tumors [41]. Finally, there is the possibility that autono-
mous cortisol secretion may escape detection by the available 
endocrine tests and lead to incorrect diagnosis of non-function-
ing tumors [26]. However, evidence suggests that a greater de-
gree of cortisol autonomy, heralded by higher cortisol levels af-
ter overnight 1 mg-DST suppression, is linked to increasing car-
diovascular risk [1,2,14]. Therefore, we need more studies to 
understand what level of cortisol autonomy is tied to clinical 
consequences. Answering this question is the key to develop 
adequate decision-making strategies concerning the choice be-
tween surgery and conservative management for patients with 
adrenal incidentalomas. 
IS IT CONCEIVABLE AN ADENOMA TO 
CARCINOMA PROGRESSION?
An important debated issue is the possibility of an adenoma to 
carcinoma progression. Clinical experiences are anecdotal and 
only few case reports are available. The only published case of 
a malignant progression is the description of a patient with a 
typical benign incidentaloma who had developed an adrenocor-
tical carcinoma 13 years later [42]. The patient underwent 5 
Table 2. Comparison among Consensus/Guidelines on Biochemical Follow-up
Consensus/Guidelines Year of publication Country Recommendation/Suggestion
Level of 
evidence
National Institutes of Health (NIH)  
consensus conference [19]
2002 United 
States
Repeat the hormonal screening (overnight 1 mg DST, urine  
catecholamines/metabolites) annually, or earlier if clinically  
indicated, for 4 years.
Exploration and management of adrenal 
incidentalomas. French Society of  
Endocrinology Consensus [20]
2008 France Repeat the hormonal screening (overnight 1 mg DST, plasma or 
urinary metanephrines) at 6 months. Then repeat overnight 1 mg 
DST at 2 years and at 5 years.
American Association of Clinical  
Endocrinologists/American Association 
of Endocrine Surgeons (AACE/AAES) 
guideline [18]
2009 United 
States
Repeat the hormonal screening (overnight 1 mg DST, plasma al-
dosterone concentration and plasma renin activity, plasma free 
metanephrine and normetanephrine, 24-hour total urinary meta-
nephrines and fractionates catecholamines) annually for 5 years.
Grade C; Evidence 
Level 3
Guidelines for the management of the 
incidentally discovered adrenal mass 
[21]
2011 Canada Clinical and hormonal follow-up using screening tests employed 
at initial evaluation annually for 4 years. Masses exhibiting  
increasing hyperfunction should be considered for surgery.
Level 3
Evidence, Grade C 
Recommendation
Italian Association of Clinical  
Endocrinologists (AME) position  
statement [1]
2011 Italy Repeat the hormonal screening (i.e., overnight 1 mg DST) in case 
of development of clinical signs of hormone excess or worsening 
of the metabolic status and cardiovascular risk profile despite  
optimal medical treatment.
Adrenal incidentaloma in adults— 
management recommendations by the 
Polish Society of Endocrinology [22]
2016 Poland Repeat the hormonal screening with the overnight 1 mg DST  
annually (screening tests for pheochromocytoma may be  
considered). Stop follow-up after 3–5 years. Patients with  
suspected subclinical hypercortisolism require more control tests.
European Society of Endocrinology/
European Network for the Study of 
Adrenal Tumors (ESE/ENSAT) 
guideline [2]
2016 Europe No further hormonal screening in patients with normal hormonal 
work-up at initial evaluation, unless there are new clinical signs 
of endocrine activity or worsening of comorbidities (i.e., hyper-
tension and type 2 diabetes). 
Hormonal re-evaluation at any time during the annual clinical  
follow-up in patient with ‘autonomous cortisol secretion’ and in 
patients with both ‘possible autonomous cortisol secretion’ and 
potentially associated comorbidities. 
Weak recommen-
dation; Evidence 
Level very low
Clinical Guidelines for the Management 
of Adrenal Incidentaloma [23]
2017 Korea In tumors larger than 2 cm, repeat annual hormone tests for 4–5 
years to check the functionality of the tumor.
Recommendation 
Level C
DST, dexamethasone suppression test.
Follow-up of Adrenal Incidentalomas
Copyright © 2020 Korean Endocrine Society www.e-enm.org 31
years of uneventful imaging follow-up. The lesion was small, 
homogeneous, non-secreting, with low HU. Several years after 
the last CT scan, a large, right, heterogeneous adrenal mass was 
found incidentally. The histology examination, after surgery, 
showed an adrenal carcinoma without any benign area (Weiss 
score 8). Bernard et al. [43] described a case of a patient operat-
ed for an adrenal incidentaloma, who had at the histological ex-
amination two different areas: a central malignant tissue sur-
rounded by an area with clear benign appearance. At molecular 
analysis, the malignant part had genomic abnormalities similar 
to other malignant tumors, while the benign did not have any 
mutations. 
In two series of patients with a definitive diagnosis of adreno-
cortical carcinoma, the imaging of adrenal gland before the di-
agnosis of malignancy were re-evaluated. Ozsari et al. [44] ana-
lyzed 25 cases of adrenal carcinoma. Only five of these had 
normal glands, instead 20 patients had pre-existing masses. 
However, none of them had the characteristic of a benign lesion: 
the masses were heterogeneous, with high HU units, diameters 
>4 cm. Thus, according to guidelines, they should have had a 
closer follow-up. Nogueira et al. [45] analyzed the images of 20 
adrenal masses before the onset of adenocarcinoma. Excluding 
the larger masses, five patients had a mass less than 2 cm in 
size, and only two of them had one or more characteristics of 
benign lesions. However, in both cases, an unenhanced CT with 
HU evaluation has not been performed, thus we could not ex-
clude a high density suggestive of malignancy.
The pathogenesis of a possible transformation from a benign 
adenoma to a malignant carcinoma remains matter of debate. A 
hypothesis suggests two different events that can occur in the 
same adrenal gland [42]. In contrast, there are data suggesting 
an adenoma to carcinoma sequence, with additional occurrence 
of mutations, as in colorectal cancer [46,47]. The pathway that 
seems to play a central role in this model is the Wnt/beta-catenin 
pathway. Tissier et al. [48] demonstrated that the activation of 
Wnt is frequent both in benign and malignant lesions in half of 
cases, especially in non-secreting tumors. The role of wnt/beta-
catenin pathway in oncogenesis have been studied particularly 
Fig. 1. Flowchart on the radiological follow-up of adrenal incidentalomas. After first radiological evaluation of adrenal masses <4 cm with 
clear radiological benign features, we suggest no further imaging in patients ages >60 years. For patients aged <60 years, we suggest one 
single imaging control after 6 to 12 months. After first radiological evaluation of adrenal masses ≥4 cm and/or uncertain radiological fea-
tures, three possibilities can be considered and should be discussed by a multidisciplinary team: immediate surgery, immediate further imag-
ing with another technique or delayed radiological re-evaluation after 6 to 12 months. If the uncertain nature of the adrenal lesion is con-
firmed, or if the imaging follow-up shows a growth >5 mm or >20%, surgery should be considered. If no changes of the lesion are observed 
at 6 to 12 months, radiological follow-up can be continued up to 2 to 4 years, depending on age and comorbidities of the patients, and then 
stopped if stability of the lesion is confirmed. CT, computed tomography; MRI, magnetic resonance imaging; FDG-PET, fluorodeoxyglu-
cose positron emission tomography.
Imaging follow-up
≥4 cm and/or
uncertain imaging
<4 cm and clear
benign imagingDiscuss with
multidisciplinary team
Immediate
further imaging
CT/MRI/FDG-PET
Confirmed uncertain
imaging?
Non-contrast CT/MRI
at 6−12 months
Non-contrast CT/MRI
at 6−12 months
If no change after 2−4 years consider
Stop follow-up
(depending on age and comorbidities)
Tumor growth
≥5 mm/20%?
<60 years old? Stop
No
Yes
Consider
Consider
Consider
Surgery
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in familial adenomatous polyposis (FAP), that is an autosomal 
dominant disease where the germline mutations of adenomatous 
polyposis coli (APC) gene determinate an alteration in the APC 
protein. Interestingly, a high incidence of adrenocortical tumors 
has been found in patients with FAP, many of them as autopsy 
findings [49]. The importance of beta-catenin pathway is dem-
onstrated also in mice model, where the presence of stabilized 
beta-catenin with a second mutation triggers the process from 
normal adrenal gland to hyperplasia and then to adenoma and 
carcinoma [50].
Moreover, it has proven that adrenal gland adenomas and car-
cinomas presented many common copy number alterations in 
the entire genome. In benign adenomas the most frequent altera-
tions were copy numbers gains, and most of them were present 
also in carcinomas. The more involved chromosomes were 4, 5, 
7, 8, 12, 16, 19, that encode for transcription factors, protein ki-
nases, oncogenes, and tumor suppressor genes. Several of these 
are also known to be associated with beta-catenin pathway. 
Many of these aberrations have been reported in other type of 
tumors, as colorectal cancer and early stage non-small-cell lung 
carcinoma, where they represent a crucial step for the tumori-
genesis [51].
The possibility that an adrenal adenoma progresses to carci-
noma is unlikely. However, it would be important to better un-
derstand this mechanism to define how and in which patients 
there is more risk to malignancy, and to develop an appropriate 
follow-up algorithm. 
CONCLUSIONS
To date, the inconsistency between official guidelines and the 
consequent diffuse uncertainty on management of small adrenal 
incidentalomas still represents a considerable problem in terms 
of clinical choices in real practice. Moreover, the increasing 
prevalence of incidentally detected adrenal masses makes this 
uncertainty also a matter of cost-effectiveness.
In relation to this point, Chomsky-Higgins et al. [52] devel-
oped a cost-effectiveness model, which evaluates different sur-
Fig. 2. Flowchart on the biochemical follow-up of adrenal incidentalomas. At first evaluation, patients with adrenal incidentaloma should 
undergo a clinical and biochemical evaluation for hormonal secretion, consisting of 1 mg-dexamethasone suppression test (DST), plasma-
free or urinary fractionated metanephrines and aldosterone/renin ratio (ARR) in patients with hypertension or unexplained hypokalemia. If 
hormonal secretion at diagnosis is excluded, biochemical follow-up is not indicated. In case of overt Cushing’s syndrome, pheochromocyto-
ma or primary hyperaldosteronism, surgery should be considered. Surgery can also be considered in patients with autonomous cortisol se-
cretion or possible autonomous cortisol secretion with related comorbidities; if surgery is not performed, patients with possible autonomous 
cortisol secretion without comorbidities should undergo a clinical follow-up after 12 months with a subsequent biochemical re-evaluation in 
case of clinical worsening. If the biochemical re-evaluation shows hormonal secretion, surgery should be considered, particularly in patients 
aged <60 years. In case of clinical and biochemical stability, biochemical follow-up can be stopped after 2 to 4 years. 
Consider <60 years old?
Consider <60 
years old?
Stop
Consider
No
Yes
Surgery
Stop follow-up
after 2−4 years 
if no change?
Hormonal follow-up
Hormonal 
re-evaluation
Appearance or worsening of related
comorbidities?
Clinical follow-up at 12 months
Clinical and biochemical evaluation
(1 mg DST, urinary meta- and normetanephrines, and in patients
with hypertension/hypokalemia plasma ARR)
Possible autonomous cortisol
secretion (1 mg DST: 1.9−5 μg/dL)
without comorbidities
Possible autonomous cortisol secretion
(1 mg DST: 1.9−5 μg/dL)+related comorbidities
or autonomous cortisol secretion (1 mg DST >5 μg/dL)
Secretion?
Secretion?
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veillance strategies for management of small (<4 cm), benign-
appearing adrenal incidentalomas. Four possible strategies were 
compared: no surveillance, single surveillance at 12 months, 
annual surveillance for 2 years, and annual surveillance for 5 
years. Surveillance included imaging (non-contrast CT) and 
biochemical testing (DST and plasma levels of renin, aldoste-
rone, and metanephrine). 
Costs were measured in 2016 United States dollars, effective-
ness in quality-adjusted life-years. The results showed that the 
two strategies with more surveillance were less effective and 
more costly, because of false positives, unnecessary surgery, ex-
posure to radiation. The strategies with no surveillance and sin-
gle surveillance dominated in terms of cost-effectiveness. In 
particular, the single surveillance strategy was cost-effective in 
younger patients (<60 years), whereas in older patients (>60 
years) the no-surveillance strategy was more effective. 
The authors conclude suggesting a management strategy sim-
ilar to what indicated by the ESE/ENSAT guidelines, but adding 
a single radiological and biochemical follow-up, especially in 
patients aged <60 years.
This strategy could maybe represent a compromise between 
the recent European guidelines and the previous ones and help 
clinicians to avoid excessive surveillance, inducing unnecessary 
radiation or surgery, without the risk of overlooking a lesion 
with malignant potential hiding beyond a benign appearance at 
detection, and with tolerable costs for society. 
Following the mainly retrospective available data we suggest 
a possible algorithm for the follow-up management of adrenal 
incidentaloma considering separately imaging and hormonal 
evaluation (Figs. 1, 2).
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